SCHEMBL830513

SCHEMBL830513

O=C(NC1CCCCC1)Oc1ccccc1Br

nearest known ligand 0.66

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.66
RAB9A P51151 2/20 0.63
ALDH1A1 P00352 1/20 0.63
LMNA P02545 1/20 0.62
HPGD P15428 1/20 0.62
HTT P42858 1/20 0.62
KMT2A Q03164 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
FAAH O00519 2/20 0.56
LHCGR P22888 1/20 0.52
GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23795440 0.95 EPHX1 (0.59) EPHX1RAB9AALDH1A1LMNAHPGD
SCHEMBL3850426 0.82 EPHX1 (0.66) EPHX1RAB9AALDH1A1FAAHLHCGR
SCHEMBL4318377 0.81 EPHX1 (0.65) EPHX1RAB9AALDH1A1FAAH
SCHEMBL20627345 0.81 LMNA (0.48) EPHX1RAB9AALDH1A1LMNAHPGD
SCHEMBL9461065 0.81 EPHX1 (0.68) EPHX1RAB9AALDH1A1LMNAKMT2A
SCHEMBL15975470 0.79 EPHX1 (0.80) EPHX1RAB9AALDH1A1HPGDKMT2A
SCHEMBL12195983 0.79 EPHX1 (1.00) EPHX1RAB9AALDH1A1FAAHLHCGR
SCHEMBL27620243 0.79 EPHX1 (0.67) EPHX1RAB9AALDH1A1KMT2AFAAH
SCHEMBL4748094 0.78 EPHX1 (0.61) EPHX1RAB9AALDH1A1FAAHLHCGR
SCHEMBL28450795 0.78 FAAH (0.50) EPHX1RAB9AALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3070085-B1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-01-09 EP disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 EPHX1 1297/4885RAB9A 3160/4885ALDH1A1 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.